| Naslov: | Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination |
|---|
| Avtorji: | ID Janžič, Urška, Klinika Golnik, Medicinska fakulteta UL (Avtor)
ID Bidovec, Urška, Klinika Golnik (Avtor)
ID Mohorčič, Katja, Klinika Golnik (Avtor)
ID Mrak, Loredana, Klinika Golnik (Avtor)
ID Fokter Dovnik, Nina (Avtor)
ID Ivanović, Marija (Avtor)
ID Ravnik, Maja (Avtor)
ID Čakš, Marina (Avtor)
ID Škof, Erik (Avtor)
ID Debeljak, Jerneja, Klinika Golnik (Avtor)
ID Korošec, Peter, Klinika Golnik, Fakulteta za farmacijo UL (Avtor)
ID Rijavec, Matija, Klinika Golnik, Biotehniška fakulteta UL (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (2,03 MB)
MD5: CA4038977033DC2EEB666EA80845FD83
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted. |
|---|
| Ključne besede: | onkološko zdravljenje, imunogenost, osnovno cepljenje mRNA, čvrsti tumorji, anticancer treatment, immunogenicity, mRNA-based vaccination, solid cancer |
|---|
| Status publikacije: | V tisku |
|---|
| Verzija publikacije: | Recenzirani rokopis |
|---|
| Kraj izida: | Velika Britanija |
|---|
| Založnik: | Future Medicine |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. [1-10] |
|---|
| Številčenje: | Vol. , iss. |
|---|
| PID: | 20.500.12556/DiRROS-15227  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1479-6694 |
|---|
| DOI: | 10.2217/fon-2022-0148 |
|---|
| COBISS.SI-ID: | 111378179 |
|---|
| Avtorske pravice: | (C) 2022 The Authors |
|---|
| Opomba: | Soavtorji: Urška Bidovec-Stojković, Katja Mohorčič, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanović, Maja Ravnik, Marina Čaks, Erik Škof, Jerneja Debeljak, Peter Korošec & Matija Rijavec;
|
|---|
| Datum objave v DiRROS: | 24.06.2022 |
|---|
| Število ogledov: | 1194 |
|---|
| Število prenosov: | 498 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
